AChE/BuChE-IN-5 

AChE/BuChE-IN-5(compound 5a) is a dual target inhibitor. AChE/BuChE-IN-5 has excellent nanomolar inhibitory activity on acetylcholinesterase (AChE)(IC₅₀=46.9 nM) and butyryl cholinesterase (BuChE)(IC₅₀=3.5 nM). AChE/BuChE-IN-5 can be used for Alzheimer's Disease research^[1].

AChE/BuChE-IN-5 inhibits acetylcholinesterase (AChE)(IC₅₀=46.9 nM) and butyryl cholinesterase (BuChE) )(IC₅₀=46.9 nM) and shows better inhibitory effects than the known dual inhibitor Rivastigmine(HY-17368) in vivo animal model of AD disease^[1]. AChE/BuChE-IN-5 has a higher BuChE selectivity than AChE, and the selectivity index (SI) is 0.07, indicating that it has a stronger inhibitory effect on BuChE^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

AChE/BuChE-IN-5(1 mg/kg, ip.; 14 days) has neuroprotective, antioxidant and anti-apoptotic effects in AD animal models^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

314.34

C₁₉H₁₄N₄O

C1(NC2=NN=C(O2)C3=CC(C4=CC=CC=C4)=CN=C3)=CC=CC=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zaafar D, et al. Unleashing new MTDL AChE and BuChE inhibitors as potential anti-AD therapeutic agents: In vitro, in vivo and in silico studies[J]. International Journal of Biological Macromolecules, 2024: 131740.  [Content Brief]